ROME—Testing for the genetic changes predicting prognosis is a key method for choosing the right therapy for your elderly patient with myelodysplastic syndrome according to Francesc Solé, Chief of th
Francesc Solé
ROME—Testing for the genetic changes predicting prognosis is a key method for choosing the right therapy for your elderly patient with myelodysplastic syndrome according to Francesc Solé, Chief of the Laboratory of Cytogenetics at the Hospital del Mar in Barcelona. He tells ecancer radio about the importance of using gene tests to help define risk in older patients.
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/110326FrancescSolePODCASTLoRes.mp3]